scholarly journals Female Reproductive and Gynecologic Considerations in Chronic Kidney Disease: Adolescence and Young Adulthood

2021 ◽  
Author(s):  
Danica H. Chang ◽  
Sandra M. Dumanski ◽  
Sofia B. Ahmed
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Young Adulthood ◽  
Adolescence And Young Adulthood

Abstract 13655: Chronic Kidney Disease Progression and Prediction of Clinical Cardiovascular Disease and Total Mortality: The Coronary Artery Risk Development in Young Adults (cardia) Study

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Daniel A Duprez ◽  
Yuni Choi ◽  
Gautam R Shroff ◽  
Haitao Chu ◽  
Holly J Kramer ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Young Adults ◽  
Kidney Disease ◽  
Young Adulthood ◽  
Proportional Hazards ◽  
Transition Probabilities ◽  
Total Mortality ◽  
Healthy Population ◽  
Ckd Stage ◽  
Risk Categories

Introduction: The Kidney Disease Improving Global Outcomes (KDIGO)Guidelines proposed a chronic kidney disease (CKD) risk assessment matrix based on estimated glomerular filtration (eGFR) together with albuminuria categories (urine albumin-to-creatinine (ACR)). This classification system tends to focus on nuances at the severe CKD end of the spectrum among middle-aged and older adults. We expanded the KDIGO risk categories to include less severe manifestations of CKD, applicable to a generally healthy population in young adulthood. Hypothesis: CKD progression in its less severe range is common and predicts CVD and total mortality starting in generally healthy young adults. Methods: In a community-based sample of black and white men and women, both eGFR (creatinine) and spot urine ACR were assayed at study year 10 (age 27-41y) and every 5 y for 20 y through year 30. We expanded the 4 KDIGO risk categories by adding 2 less severe categories (see Figure). We estimated CKD stage prevalence at each exam and transition probabilities, including 4389 participants by year 30. We used proportional hazards regression with time-varying CKD stage, age, sex, and race as predictors of the endpoints any incident CVD or total death. Results: As expected, extreme risk was seen in 131 people (3% prevalence) who reached stages 4-6 (See Figure). Important increases in risk (hazard ratios 1.55 to 3.11) occurred in 1601 people (36% prevalence) who reached stages 2-3. Transition to higher stage (mostly by 1 stage) occurred in 5-10% per 5 years (~30% in 20 years). Conclusions: These data suggest that clinically important changes occur in CKD risk staging throughout middle age, though most of these changes are currently regarded as minor occurrences. Research should explore whether more aggressive, low risk treatment options, which currently exist, would be beneficial in people with small changes in CKD stage, starting in young adulthood.

No effect of vitamin D supplementation on metabolic parameters but on lipids in patients with type 2 diabetes and chronic kidney disease

2020 ◽  
pp. 1-10
Author(s):  
Jiwoon Kim ◽  
Ji Sun Nam ◽  
Heejung Kim ◽  
Hye Sun Lee ◽  
Jung Eun Lee
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Supplementation ◽  
Lipid Profiles ◽  
Metabolic Parameters ◽  
Injection Group ◽  
Different Doses

Abstract. Background/Aims: Trials on the effects of cholecalciferol supplementation in type 2 diabetes with chronic kidney disease patients were underexplored. Therefore, the aim of this study was to investigate the effects of two different doses of vitamin D supplementation on serum 25-hydroxyvitamin D [25(OH)D] concentrations and metabolic parameters in vitamin D-deficient Korean diabetes patients with chronic kidney disease. Methods: 92 patients completed this study: the placebo group (A, n = 33), the oral cholecalciferol 1,000 IU/day group (B, n = 34), or the single 200,000 IU injection group (C, n = 25, equivalent to 2,000 IU/day). 52% of the patients had less than 60 mL/min/1.73m2 of glomerular filtration rates. Laboratory test and pulse wave velocity were performed before and after supplementation. Results: After 12 weeks, serum 25(OH)D concentrations of the patients who received vitamin D supplementation were significantly increased (A, -2.4 ± 1.2 ng/mL vs. B, 10.7 ± 1.2 ng/mL vs. C, 14.6 ± 1.7 ng/mL; p < 0.001). In addition, the lipid profiles in the vitamin D injection group (C) showed a significant decrease in triglyceride and a rise in HDL cholesterol. However, the other parameters showed no differences. Conclusions: Our data indicated that two different doses and routes of vitamin D administration significantly and safely increased serum 25(OH)D concentrations in vitamin D-deficient diabetes patients with comorbid chronic kidney disease. In the group that received the higher vitamin D dose, the lipid profiles showed significant improvement, but there were no beneficial effects on other metabolic parameters.

Ankle-brachial index in chronic kidney disease

VASA ◽  
2012 ◽  
Vol 41 (3) ◽  
pp. 159-160
Author(s):  
Espinola-Klein ◽  
F. Dopheide ◽  
Gori
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Ankle Brachial Index
Sign in / Sign up

Export Citation Format

Share Document